Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.

Liu D, Rodriguez GD, Zhou H-, Cheng Y-, Li X, Tang W, et al. SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection. Int J Mol Sci. 2022;23(11).

Koeller DR, Manning DK, Schwartz A, Chittenden A, Hayes CP, Abraamyan F, et al. An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: Using somatic genome to inform the role of germline variants. MethodsX. 2022;9:101761.

Hao Y, Yang HS, Karbaschi M, Racine-Brzostek SE, Li P, Zuk R, et al. Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients. Biosens Bioelectron. 2022;209:114237.

Wulff RT, Qiu Y, Wu C, Calfee DP, Singh HK, Hatch I, et al. Laboratory Interventions to Eliminate Unnecessary Rapid COVID-19 Testing During a Reagent Shortage. Am J Clin Pathol. 2022;158(3):401-408.

Nassar AH, Adib E, Alaiwi SA, Zarif TE, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.

Charpentier M, Spada S, Van Nest SJ, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol. 2022;86(Pt 2):737-747.

Chen B-, Tyler JK, Sleckman BP. A Flow Cytometry-Based Method for Analyzing DNA End Resection in G0- and G1-Phase Mammalian Cells. Bio Protoc. 2022;12(10):e4413.

Lebowitz E, Kim JS, Magro C. Reactive arthritis following COVID-19 vaccination with BNT162b2. JAAD Case Rep. 2022;24:108-111.

Yuen CA, Hsu J-, Van Besien K, Reshef R, Iwamoto FM, Haggiagi A, et al. Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. J Immunother. 2022;45(5):254-262.